Compound Detail
CHEMBL2348780
VAMOROLONE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@@]1(O)C(=O)CO
Basic Information
| ChEMBL ID | CHEMBL2348780 |
| Name | VAMOROLONE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | ZYTXTXAMMDTYDQ-DGEXFFLYSA-N |
| Therapeutic | ✓ Yes |
3
Targets
3
Activities
2
Assay Types
19
PK Parameters
18
Publications
8
Known Names
3
Indications
2
Mechanisms
Molecular Properties
356.5
MW (Da)
2.75
ALogP
4
HBA
2
HBD
74.6
PSA (Ų)
0.75
QED
0
Ro5 Violations
2
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2023 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Glucocorticoid receptor agonist | AGONIST | Glucocorticoid receptor | ✓ | ✓ |
| Mineralocorticoid receptor antagonist | ANTAGONIST | Mineralocorticoid receptor | ✓ | ✓ |
Indications
Muscular Dystrophy, Duchenne Muscular Dystrophy, Duchenne Colitis, Ulcerative
ATC Classification
H02AB18
vamorolone
Level 1: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
Level 2: CORTICOSTEROIDS FOR SYSTEMIC USE
Activity Summary
IC50 2 meas. best 7.18
EC50 1 meas. best 7.18
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Nuclear factor NF-kappa-B complex CHEMBL2094258 | IC50 | 7.18 | 7.18 | 65.9 | 1 |
| Unchecked CHEMBL612545 | EC50 | 7.18 | 7.18 | 65.9 | 1 |
| Voltage-gated inwardly rectifying potassium channel KCNH2 CHEMBL240 | IC50 | 4.7 | 4.7 | 20000.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 32912.0 | ng.hr.mL-1 | Mus musculus |
| AUC | 8838.0 | ng.hr.mL-1 | Mus musculus |
| CL | 20.2 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 24.7 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 18.8 | mL.min-1.kg-1 | Mus musculus |
| F | 53.2 | % | Canis lupus familiaris |
| F | 47.8 | % | Rattus norvegicus |
| F | 74.5 | % | Mus musculus |
| MRT | 0.667 | hr | Mus musculus |
| T1/2 | 2.25 | hr | Canis lupus familiaris |
| T1/2 | 5.42 | hr | Canis lupus familiaris |
| T1/2 | 2.29 | hr | Rattus norvegicus |
| T1/2 | 0.58 | hr | Rattus norvegicus |
| T1/2 | 0.678 | hr | Mus musculus |
| T1/2 | 0.354 | hr | Mus musculus |
| Tmax | 6.0 | hr | Canis lupus familiaris |
| Tmax | 4.0 | hr | Rattus norvegicus |
| Tmax | 2.0 | hr | Mus musculus |
| Tmax | 0.0833 | hr | Mus musculus |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| Unchecked | EC50 | = | 65.9 | nM | 7.18 | Inhibition of TNFalpha-induced NFkappaB activation in mouse C2C12 cells incubate... | 23498916 |
| Nuclear factor NF-kappa-B complex | IC50 | = | 65.9 | nM | 7.18 | Inhibition of NF-kappaB (unknown origin) | 38569434 |
| Voltage-gated inwardly rectifying potassium channel KCNH2 | IC50 | = | 20000.0 | nM | 4.7 | Inhibition of human ERG | 23498916 |
Literature References
Data from ChEMBL 36 via Core Engine